Toni Wall Jaudon
Role not yet determined Is this you? Add your title
Also affiliated: University of California, San Francisco (2023); Patient-Led Research Collaborative (2023–2024)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Toni Wall Jaudon's research focuses on the clinical and research considerations surrounding Long COVID, also known as Post-Acute COVID-19 Syndrome. She has published work examining the impact of extended-course nirmatrelvir/ritonavir treatment in individuals with established Long COVID, presenting findings from case series. Her work also addresses the design and optimization of clinical trials specifically for Long COVID research, emphasizing the need for patient-researcher collaboration. Jaudon's scholarship includes 12 publications with 161 citations and an h-index of 6. She collaborates with S Saniya at the University of Arkansas for Medical Sciences, with whom she shares one publication.
Metrics
- h-index: 6
- Publications: 12
- Citations: 167
Selected Publications
-
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series (2025)
-
A call from patient-researchers to advance research on long COVID (2024)
-
Designing and optimizing clinical trials for long COVID (2024)
-
Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations (2023)
-
Interview: Obeah’s cultural politics – a conversation with Diana Paton (2015)
-
Obeah’s Sensations: Rethinking Religion at the Transnational Turn (2012)
Collaboration Network
Top Collaborators
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Designing and optimizing clinical trials for long COVID
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- A call from patient-researchers to advance research on long COVID
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Designing and optimizing clinical trials for long COVID
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- A call from patient-researchers to advance research on long COVID
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Designing and optimizing clinical trials for long COVID
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- A call from patient-researchers to advance research on long COVID
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
- Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
- Designing and optimizing clinical trials for long COVID
- A call from patient-researchers to advance research on long COVID
- Designing and optimizing clinical trials for long COVID
- A call from patient-researchers to advance research on long COVID
Similar Researchers
Based on overlapping research topics